Mobile

A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-002570-30

A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Neuroprotection: Reduction in the risk of occurrence of Grade 3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.

Critère d'inclusion

  • Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV at risk of cumulative peripheral sensory neuropathy PSN relative to cumulative dose of oxaliplatin

Liens